Biopharmaceutical company GeNeuro (Euronext Paris:CH0308403085 – GNRO) stated on Monday its net loss of EUR8.96m (EUR0.45 basic losses per share) for the year ended 31 December 2020.
This is compared with a higher net loss of USD9.46m (EUR0.65 basic losses per share) in 2019.
Due to its development stage, the company generated no income in 2020 or 2019.
Research & Development expenses of EUR4.71m was recorded in 2020, a decline by 24% over EUR6.18m in 2019, due to decrease in clinical trial costs and decrease in R&D payroll expense as the company adjusted its staffing levels to its current activity profile.
As of 31 December 2020, the cash and cash equivalents was EUR6.8m, a rise versus EUR5.9m from 31 December 2019, due to the EUR17.5m capital increase completed in January 2020.
The company's operations funded until Q2-2022, the clinical trial of temelimab in multiple sclerosis (MS) with Karolinska Institutet/Academic Specialist Center of Stockholm, is on track to deliver results in Q1 2022 and the preliminary results on the role of the HERV-W Env protein in severe COVID-19 syndromes may lead in the short term to new indications for temelimab.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development